Pacific Biosciences of California (PACB) Projected to Post Earnings on Thursday

Pacific Biosciences of California (NASDAQ:PACB) is anticipated to issue its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect Pacific Biosciences of California to post earnings of ($0.19) per share and revenue of $44.60 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 12, 2026 at 5:00 PM ET.

Pacific Biosciences of California Stock Down 1.6%

PACB stock opened at $1.81 on Wednesday. The company has a debt-to-equity ratio of 17.88, a current ratio of 6.24 and a quick ratio of 5.40. The company’s 50 day simple moving average is $2.11 and its 200-day simple moving average is $1.77. Pacific Biosciences of California has a 12 month low of $0.85 and a 12 month high of $2.73. The firm has a market capitalization of $546.46 million, a PE ratio of -0.82 and a beta of 2.27.

Wall Street Analysts Forecast Growth

PACB has been the subject of several recent research reports. Barclays raised their price target on Pacific Biosciences of California from $1.50 to $2.00 and gave the stock an “equal weight” rating in a research report on Monday, December 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pacific Biosciences of California in a research report on Thursday, January 22nd. Piper Sandler upped their target price on shares of Pacific Biosciences of California from $1.50 to $2.00 and gave the company a “neutral” rating in a report on Tuesday, November 11th. Finally, Stephens raised their price target on shares of Pacific Biosciences of California from $1.80 to $2.00 and gave the stock an “overweight” rating in a research note on Monday, November 10th. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Pacific Biosciences of California currently has a consensus rating of “Hold” and an average price target of $2.08.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of PACB. Millennium Management LLC boosted its position in shares of Pacific Biosciences of California by 500.9% in the third quarter. Millennium Management LLC now owns 4,916,795 shares of the biotechnology company’s stock worth $6,293,000 after acquiring an additional 4,098,555 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Pacific Biosciences of California by 170.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 1,378,872 shares of the biotechnology company’s stock worth $2,578,000 after purchasing an additional 869,445 shares during the last quarter. Bank of America Corp DE raised its stake in Pacific Biosciences of California by 109.6% during the third quarter. Bank of America Corp DE now owns 1,472,690 shares of the biotechnology company’s stock worth $1,885,000 after purchasing an additional 769,987 shares during the period. Two Sigma Investments LP acquired a new position in shares of Pacific Biosciences of California in the 3rd quarter valued at $514,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Pacific Biosciences of California by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 16,379,972 shares of the biotechnology company’s stock valued at $20,966,000 after purchasing an additional 362,797 shares during the last quarter.

Pacific Biosciences of California Company Profile

Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company’s proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.

Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.